TerminatedPhase 3NCT04876716

Azole-echinocandin Combination Therapy for Invasive Aspergillosis

Studying Aspergillosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Erasmus Medical Center
Principal Investigator
Bart Rijnders, MD, PhD
Erasmus Medical Center
Intervention
Azole(drug)
Enrollment
66 enrolled
Eligibility
18 years · All sexes
Timeline
20212024

Study locations (4)

Collaborators

ZonMw: The Netherlands Organisation for Health Research and Development · Stichting Hemato-Oncologie voor Volwassenen Nederland

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04876716 on ClinicalTrials.gov

Other trials for Aspergillosis

Additional recruiting or active studies for the same condition.

See all trials for Aspergillosis

← Back to all trials